Barclays Initiates Coverage On Monopar Therapeutics with Overweight Rating, Announces Price Target of $125
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
Barclays analyst Etzer Darout initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Overweight rating and announces Price Target of $125.
Barclays analyst Etzer Darout initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Overweight rating and announces Price Target of $125.